In partnership with
Newly diagnosed older AML: new standard of care
Haemoglobinopathies: worse COVID-19 outcomes?
Daratumumab for light-chain amyloidosis
PET-stratification can omit radiotherapy in early-stage unfavourable Hodgkin lymphoma
Ruxolitinib improves steroid-refractory acute GVHD across subtypes
Irradiation + chemotherapy is better than chemotherapy alone for children getting stem cell transplantation
Paroxysmal nocturnal haemoglobinuria treatment with pegcetacoplan
Pembrolizumab improves PFS for relapsed/refractory Hodgkin lymphoma
Patients with lower-risk MDS benefit from imetelstat
Isatuximab triplet improves PFS in R/R MM
Top image: @ iStockPhoto: PhonlamaiPhoto
The content and interpretation of these conference highlights are the views and comments of the speakers/ authors.
BACK TO TOP